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Abstract
Gene therapy for sickle cell disease will require efficient delivery of a tightly regulated and stably expressed gene product to
provide an effective therapy. In this study we utilized the non-viral Sleeping Beauty (SB) transposon system using the SB100X
hyperactive transposase to transduce human cord blood CD34
+ cells with DsRed and a hybrid IHK–b-globin transgene. IHK
transduced cells were successfully differentiated into multiple lineages which all showed transgene integration. The mature
erythroid cells had an increased b-globin to c-globin ratio from 0.6660.08 to 1.0560.12 (p=0.05), indicating expression of
b-globin from the integrated SB transgene. IHK–b-globin mRNA was found in non-erythroid cell types, similar to native b-
globin mRNA that was also expressed at low levels. Additional studies in the hematopoietic K562 cell line confirmed the
ability of cHS4 insulator elements to protect DsRed and IHK–b-globin transgenes from silencing in long-term culture studies.
Insulated transgenes had statistically significant improvement in the maintenance of long term expression, while preserving
transgene regulation. These results support the use of Sleeping Beauty vectors in carrying an insulated IHK–b-globin
transgene for gene therapy of sickle cell disease.
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Introduction
Hematopoietic stem cells (HSCs) are an attractive target for
genetic modification to treat diseases such as sickle cell anemia, b-
thalassemia, and severe combined immunodeficiency (SCID),
among others [1,2]. The ability of HSCs to be harvested with
relative ease, withstand ex vivo manipulation and their long
established clinical use in transplants allows for numerous potential
gene therapy strategies. This is supported by a recent report of
successful treatment of a b-thalassemia patient using a recombinant
hemoglobin-expressing lentivirus to transduce autologous CD34
+
cells [3]. However, as in other viral vector clinical trials, significant
and potentially problematic clonal expansion was observed.
HSCs give rise to a diverse number of cell types and maintain
their ability to self-renew [4,5]. The current methods for gene
transfer in clinical trials rely principally on the use of modified
retroviruses such as Moloney murine leukemia virus (MMLV) and
lentivirus, which have been known to insert into actively
transcribed genes and potentially promote oncogenesis [6–8].
The development of leukemia in 4 out of 20 patients enrolled in a
trial of MLV-based therapy for X-SCID continues to be a
cautionary example to the field of gene therapy [9,10].
Non-viral vectors offer a more easily implemented and
potentially safer method to genetically modify cells [11–13].
Non-viral vectors, however, are challenged by relatively low gene
transfer efficiency and the difficulty of maintaining long-term
stable expression [13–15]. Transposons can be utilized to provide
an integration mechanism for stable copy number and long-term
expression important for non-viral gene therapies [16–19]. The
Sleeping Beauty (SB) transposon system has become increasingly
useful in fields ranging from cancer biology and stem cell research
to gene therapy over the last decade since its resurrection from the
salmonid genome [17,20,21]. The recent development of the
SB100X transposase and its utility in modifying primary CD34
+
cells are evidence of the system’s continued improvements and
potential clinical significance [22,23].
In this study, we used the SB transposon to develop an optimal
expression system for erythroid-specific gene expression in specific
lineages [24]. Typical viral vectors drive erythroid-specific b-
globin expression using 2.7 kilobases (kb) from the b-globin locus
control region and promoter [25]. This large size makes the
approach impractical for the SB system, which loses efficiency in a
linear fashion from 2-kb cargos up to a practical limit of 6–10 kb
[16,22]. The 1-kb erythroid promoter IHK can provide high-level
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promoter is composed of the ALAS2 intron 8 strong erythroid
enhancer, the HS40 core element upstream from the f-globin
gene, and the Ankryin-1 promoter [27].
Even with improved integration efficiency and transgene design,
the SB transposon system is still subject to epigenetic changes in
the host genome such as DNA methylation, and histone
modification [28–30]. In a recent report, the heterologous chicken
HS4 b-globin insulator elements (cHS4) flanking a fluorescent
transgene were employed in SB vectors and provided protection
against progressive silencing of transposon integration sites [21].
This chicken HS4 insulator element was able to block enhancer
activity, eliminating or diminishing the influence of enhancer
elements on genes in close proximity [31,32]. In addition, it has
been shown to protect transgenes from silencing by epigenetic
modifications such as CpG methylation when the transgene is
flanked on both sides by cHS4 insulator elements [33,34].
Furthermore, this enhancer blocking activity of the insulator
may mitigate the potential transactivation of neighboring host
genes by SB-mediated transgene insertion, which has been
observed in a few insertion loci in previous studies [28,35].
In this study, the IHK-b-globin gene was used in combination
with the SB100X transposase system to provide erythroid-specific
expression of b-globin when integrated into primary CD34
+ cells,
and differentiated into multiple lineages. In addition, our results
confirmed previous reports that the incorporation of insulator
elements into the SB construct(s) protects transgenes against long-
term inactivation, possibly from epigenetic changes, which reduce
expression of integrated transgenes over time [21,35]. Together,
the results support the potential use of a SB IHK–b-globin
expression system for the gene therapy of sickle cell disease in
human clinical trials.
Results
SB100X transduces CD34
+ cells in cis or trans
To test the utility of a cis SB100X construct, 5610
5 CD34
+ cells
from freshly isolated cord blood were mock-nucleofected with no
DNA, nucleofected with either 10 mg of pKT2/CAGGS-DsRed,
10 mg of pKT2/CAGGS-DsRed plus 5 mg of UbC-SB100X, or
10 mg of pKT2/meIF-SB100X-CAGGS-DsRed and recovered for
2 hours (Figure 1A). Cells were evaluated in standard CFU
assays. In the non-transposase pKT2/CAGGS-DsRed condition,
we observed no DsRed positive colonies at 14–16 days and
comparable viability to the cis plasmid post-nucleofection (data not
shown). The ability of SB100X to transduce hematopoietic cells
and the effect of nucleofected DNA on colony yields was assessed.
The cis SB100X vector averaged 5% DsRed
+ colonies compared
with 8% for the trans SB100X vector (Figure 1B). Nucleofection
resulted in DNA-induced toxicity with 51% viability with the cis
vector and 34% in trans when normalized to mock-nucleofected
controls (Figure 1C). DsRed
+ cells were observed in BFU-E,
CFU-GM, and CFU-GEMM cell types in both trans and cis, but
not in the non-transposase controls (Figure 1D, cis shown;
Figures S1 and S2). In addition, some single colonies displayed
heterogeneous expression patterns (Figure 1E, cis shown; Figure
S3), suggesting variable epigenetic changes.
Nucleofected CD34
+ cells differentiate in vitro
To assess the erythroid specificity of the IHK promoter, we
differentiated nucleofected CD34
+ cells from cord blood into
multiple lineages from both myeloid and lymphoid classes. CD34
+
cells (7.5610
5 to 1610
6, .90% CD34
+) obtained from three
separate umbilical cords were nucleofected with 10 mg of pKT2/
meIF-SB100X-IHK-b-Globin (Figure 2A). Cells were incubated
for two hours in recovery media with cytokines and seeded into
differentiation cultures for granulocytic, erythrocytic, B-cell, T-
cell, and myelocyte/monocyte development. Differentiated cul-
tures were assessed for granulocyte, erythrocyte, B-cell, T-cell, and
myelocyte/monocyte development by identification of surface
markers using flow cytometry (Figure 2D). Granulocytes showed
robust differentiation with over 90% of CD15
+ cells after ten days.
In contrast, B-cell cultures demonstrated ,10% CD19 expression
at 3 weeks, consistent with previous reports on differentiation
without specific enrichment [36]. T-cell cultures were associated
with .90% CD7
+ cells and 30% CD1a
+/CD7
+ cells at 4 weeks.
Myelocyte/monocyte cultures showed just over 40% of cells
expressing CD14, CD33, or both. Erythroid cultures demonstrat-
ed that .95% of cells expressed CD235a and ,20% had
enucleated by 18 days as determined by DRAQ5 staining. The
erythroid cultures were followed from a low density seeding (day 0)
through expansion and seeding onto a confluent MS-5 feeder layer
(days 8 and 11, respectively) to maturation and hemoglobinization
(days 15 and 18; Figure 2B). By day 18, nucleated erythroid cells,
enucleated biconcave cells, and recently enucleated cup-shaped
cells were apparent throughout the culture (black arrows left-to-
right; Figure 2C).
IHK-b-globin transgene mediates erythroid-specific
hemoglobin expression
To test IHK-b-globin transgene expression, purified genomic
DNA, RNA, and protein was isolated from differentiated
erythrocytes, granulocytes, myelocytes/monocytes, B-cells, and
T-cells and examined for IHK–b-globin. The IHK–b-globin gene
was detected in genomic DNA from all trials, while SB100X
coding sequence was found in 10 of 15 trials using a highly
sensitive PCR assay (Figure 3, trial 1). Optimization of multiplex
genomic PCR demonstrated an ability to detect SB100X DNA
down to 3 copies (Figure S4). In two of the three erythroid trials
the SB100X-coding sequence was not detectable, likely attribut-
able to a lower seeding density and a higher level of expansion
compared to other lineages. Expression of b-globin in the
differentiated populations was determined by western blotting
with conditions optimized to detect as little as 3 ng of adult
hemoglobin spiked into 50 mg of white blood cell lysate (Figure
S5). Both IHK–b-globin transduced and control erythroid cultures
showed robust b-globin expression, while expression was not
detectable in the non-erythrocyte lineages (Figure 4; Figures S6
and S7). HPLC analysis of hemoglobin from control and IHK
transduced-erythroid cells showed a significant increase (p,0.05)
in the ratio of b-globin to c-globin from 0.6660.08 to 1.0560.12
in the three IHK transduced erythroid cultures relative to the
three control cultures (Figure 5).
b-globin transcript is increased in non-erythroid progeny
of IHK-transduced CD34
+ cells while SB100X transcript is
undetectable
RNA from differentiated cells derived from IHK-transduced
CD34
+ cells was subjected to RT-PCR using primers specific for
b-actin and b-globin (Figure 6; Figures S8 and S9). All sets of
samples showed similar levels of b-actin. Erythroid cells had
increased b-globin transcript expression with the IHK-b-globin
compared to control erythroid cells. Interestingly, the b-globin
transcript was found in both the WBC control and at a higher level
in the non-erythroid cells derived from IHK-transduced CD34
+
cells. Because copies of SB100X-coding sequence were found to be
carried in some transduced cells, RT-PCR for SB100X RNA was
Erythroid-Specific Expression from Sleeping Beauty
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(data not shown), thereby excluding the possibility of SB
transposon mobility at this stage.
Protection of transgene from progressive silencing by
cHS4 insulator elements
cHS4 insulator elements were introduced into the SB transpo-
son vector system to test whether cHS4 insulator elements can
provide protection against progressive silencing of the transgene
[21,28,30]. The CAGGS-DsRed transgene cassette was cloned
into a helper-independent cis SB vector containing the hyperactive
SB transposase, SB100X, as pKT2/meIF-SB100X-Ins-CAGGS-
DsRed-Ins (Figure 7A). In this construct, each boundary of the
CAGGS-DsRed transgene cassette was flanked by a complete 1.2-
kb cHS4 insulator element placed in parallel to limit potential
homologous recombination between the two elements. K562
erythroid cells were transfected with pKT2/meIF-SB100X-Ins-
CAGGS-DsRed-Ins or non-insulated control, pKT2/meIF-
SB100X-CAGGS-DsRed. Two days after transfection, cells
positive for DsRed were sorted into 96-well plates at a density
less than 1 cell per well for both groups of transfected cells. Single-
cell clones were isolated by either manual selection or FACSAria
cell sorting. These clones were examined for the expression of
DsRed on the 96-well plates, and DsRed-positive clones were
further expanded to 24-well plates. Initially, 67 independent
DsRed-positive clones from cells transfected with the insulated
pKT2/meIF-SB100X-Ins-CAGGS-DsRed-Ins vector and 56 in-
dividual DsRed-positive clones from K562 cells transfected with
non-insulated control pKT2/meIF-SB100X-CAGGS-DsRed vec-
tor were isolated by FACSAria or manual selection.
Between 2 and 4 weeks after transfection, each single-cell-
derived clonal population was collected and analyzed for DsRed
expression by flow cytometry. The expression of DsRed in clones
was assessed once again at 13 to 15 weeks post-transfection, by
using parameters normalized to the initial analysis at 2 to 4 weeks
after transfection. Clones derived from cHS4-insulated SB
constructs maintained the mean intensity of DsRed expression as
well as the proportion of DsRed-positive cells at 13–15 weeks post-
transfection when compared with the initial data obtained at 2–4
weeks. This was in contrast to clones from the non-insulated
control SB vectors demonstrating long-term silencing as noted by
significant decrease in the mean intensity of DsRed expression and
percent DsRed
+ cells (Figures 7B and C). While the majority of
clones in both trials maintained relatively stable expression,
comparison of clones showing the greatest losses and gains in
percent DsRed
+ cells for each vector demonstrated the potential
for non-insulated transgenes to be highly down-regulated and
insulated transgenes to gain expression over time. DsRed
expression profiles of the 5 highest ranked clones for negative
and positive shifts from each SB vector during long-term culture
Figure 1. SB100X Transduction of CD34
+ cells in cis and trans configurations. (A) Schematics of cis and trans Sleeping Beauty plasmid vectors
(not to scale). (B) Percentage of DsRed
+ CFUs in cis or trans.( C) Colony Forming Units (CFU) derived from CD34
+ cells nucleofected with 10 mgo fcis
pKT2-meIF-SB100X-CAGGS-DsRed or 10 mgo ftrans pKT2/CAGGS-DsRed and 5 mg of UbC-SB100X using split cell samples. Totals from 4 replicates per
vector per cord were normalized to non-nucleofected CFU output to give CFU viability. (D) Colonies were scored by standard light microscopy (1506
magnification) for CFU type (top row) and epifluorescence microscopy for DsRed expression (bottom row). DsRed
+ cells were found among CFU-GM
(left panels), BFU-E (center panels), and CFU-GEMM (right panels). Cis constructs shown. (E) DsRed
+ colonies were not homogeneous in expression
patterns suggesting position effect variegation and epigenetic changes after transgene integration.
doi:10.1371/journal.pone.0029110.g001
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clones showed little change between the time points.
To test the effect of the insulators on long-term b-globin
transgene expression, we transfected K562 cells with the cHS4-
insulated b-globin-expressing vector pKT2/meIF-SB100X-IIbgI
and the non-insulated control pKT2/meIF-SB100X-Ibg. Two
days after transfection, single cells were sorted manually and
cultured in 96-well plates for two weeks, transferred to 24-well
plates for 2-weeks and analyzed for genomic IHK by PCR. For
IHK
+ clones, hemin and non-hemin treated samples were
collected at 4 and 14 weeks. Quantification of b-globin protein
expression in hemin-induced samples at both time points showed a
Figure 2. Nucleofected CD34
+ cells retain their ability to differentiate in vitro. (A) Schematic of cis IHK–b-globin SB construct (not to scale).
(B) Photomicrographs (1006total magnification) show the progression through 18 days of erythroid differentiation. (C) Erythroid differentiation can
proceed through enucleation of mature cultured red blood cells (cRBCs); black arrows from left-to-right: nucleated erythroid, enucleated biconcave,
and recently enucleated cup-shaped cells in culture at day 18 (4006total magnification; black scale bar is 10 mm in length). (D) Each differentiation
trial was stained for respective markers of differentiation at 1:100 dilutions in staining buffer. Gates were set using isotype controls or unstained
controls as appropriate. A minimum of 5610
3 singlet events was collected for each sample. Granulocyte cultures were stained with CD15-PE-Cy7 (left
panel); erythrocyte cultures with CD235a-FITC and DRAQ-5 at 1:2000 (center left panel); B-cell cultures were stained for CD19-AlexaFluor700 (center
panel); T-cell cultures with CD1a-FITC and CD7-AlexaFluor700 (center right panel); and myelocyte/monocyte cultures were stained with CD14-V450
and CD33-AlexaFluor700 (right panel).
doi:10.1371/journal.pone.0029110.g002
Figure 3. Transduced CD34
+ cells retain IHK transgene after
expansion and differentiation. Total genomic DNA of 60 ng was
PCR-amplified to detect the presence of IHK–b-globin, SB100X, and b-
actin control.
doi:10.1371/journal.pone.0029110.g003
Figure 4. IHK-transduced CD34
+ cells show b-globin expression
only in erythroid cells. Thirty mg of total protein from IHK-transduced
CD34
+ cells differentiated into T-cells, B-cells, myeloid/monocytes, and
granulocytes and 100 ng of total protein from non-transduced control
or IHK-transduced CD34
+ cells differentiated into erythrocytes were
subjected to western blot using antibodies specific for b-globin and b-
actin.
doi:10.1371/journal.pone.0029110.g004
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relative to the insulated vectors (Figure 8A). The change
represents a mean loss of 13.1681.6% of b-globin expression in
the insulated group and of 66.1650.3% of b-globin expression in
the non-insulated group. In summary, the results were similar to
those generated with the insulated and non-insulated SB vectors
for DsRed. To investigate the effect of the insulators on IHK–b-
globin regulation we tested the response of clones in each group to
induction with hemin, which stimulates hemoglobin production
and upregulation of erythroid-associated genes [37]. Induced
clones from the insulated and non-insulated groups showed no
significant differences (1.8861.29 fold and 1.7761.75 fold
increases, respectively) in b-globin expression upon hemin
induction (Figure 8B).
Discussion
In this study we have shown that primary human CD34
+ cells
can be transduced with the SB construct, pKT2/meIF-SB100X-
IHK-b-globin, can express hemoglobin in mature erythroid
progeny, while maintaining tight, erythroid-specific expression.
Previous studies have shown that IHK is potentially a more active
promoter than the b-globin LCR, albeit in a viral vector. The
small size of IHK relative to b-globin LCR/promoter-based
vectors makes it well suited for the SB system as a mechanism to
drive hemoglobin expression [22,27]. It is important to reduce the
overall size of the SB transgene cargo to promote efficient
transposition and to lower the number of insertion sites necessary
to provide therapeutic expression [22]. An interesting feature of
IHK is its use of erythroid enhancer and promoter elements,
which are not directly involved in normal b-globin production.
While the IHK acts as a strong promoter in erythroid cells, we
have previously shown that the native introns and untranslated
regions of the b-globin gene are crucial for high-level expression of
protein [26].
Analysis of the transgene content and expression of pKT2/
meIF-SB100X-IHK-b-globin transduced cells showed that each of
the nucleofected trials retained the IHK transgene in each lineage
after 18 to 28 days of differentiation. In this study, as previously
shown, we did find a low-level of transcription in non-erythroid
cells, which was translationally suppressed and failed to produce
detectable b-globin [26]. In that the inserted transposon still
contains IR/DRs necessary for transposition, the potential
remobilization of the transposon is a significant concern. We
found that SB transposase-coding DNA can be detected at low
levels within a transduced population but does not express
detectable mRNA as determined by RT-PCR, consistent with a
recent study of SB transduced cells [38].
In order to achieve maximum efficiency of transposon insertion
into the host genome, we employed an enhanced transposase,
SB100X, which was shown to be ,100 times as active as the
original version of the Sleeping Beauty transposase [39]. Stable gene
transfer efficiencies of almost 50% were achieved with SB100X in
the human cells differentiated from transfected hematopoietic
CD34
+ cells in remarkable contrast to stable gene transfer
efficiencies of the original SB transposase (0.2 to 1%) or of
second-generation hyperactive SB11 [16]. These previous results
support the potential use of SB100X as a gene transfer agent for
human CD34
+ hematopoietic cells, and further development of
the SB system in general.
We have also shown that cHS4 insulator elements can mitigate
the tendency for SB-inserted transgenes to be inactivated over the
long-term [30]. Long-term stable expression of a therapeutic
transgene is critical in the successful gene delivery for genetic
diseases such as b-thalassemia or sickle cell anemia. There are
numerous reports of transgene silencing associated with delivery
by either retroviral vectors or non-viral SB vectors [30,40]. Most of
this long-term inactivation of transgenes can be attributed to
epigenetic changes such as DNA methylation or chromatin
modifications in the inserted transgenes [29,30,41]. The chicken
HS4 insulator element employed here has previously been shown
to block enhancer activity, eliminating or diminishing the
influence of enhancer elements on genes in close proximity
whether the enhancer is included within the transgene or placed
close to the insertion site in the host genome [31,32]. In addition,
the cHS4 insulator is known to protect transgene from silencing by
Figure 5. IHK-transduced CD34
+ progenitors increase b-globin
expression in erythroid progeny. Hypotonic lysates from fetal RBCs
from the donor cords, erythrocytes from non-transduced CD34
+ cells,
and erythrocytes from IHK-transduced CD34
+ cells were analyzed by RP-
HPLC to determine relative quantities of individual globin chains. Data
from three trials are presented as mean 6 SEM, * indicates p,0.05,
paired t-test.
doi:10.1371/journal.pone.0029110.g005
Figure 6. Increased b-globin transcript is detectable in non-
erythroid progeny of IHK-transduced CD34
+ cells. Twenty ng of
total RNA was used for RT-PCR specific for spliced b-globin transcript
and spliced b-actin. RNA from adult RBCs and erythrocyte-depleted
adult WBCs was used as control.
doi:10.1371/journal.pone.0029110.g006
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transgene is flanked by cHS4 insulator elements [33,34].
In this study, cHS4 insulator elements successfully in protected
both CAGGS-DsRed and IHK–b-globin transgenes from pro-
gressive silencing in the context of SB transposon system.
Importantly, we showed that a cHS4-flanked transgene prevented
sharp inactivation of the transgene and in some cases increased
transgene expression over the ,14-week culture period. The
results are consistent with a previous report in which the insulators
prevented long term silencing of a yellow fluorescent protein
Figure 7. cHS4 insulator elements maintain long-term DsRed expression. (A) SB vectors insulated by cHS4 elements or non-insulated
control SB vectors. CAGGS promoters with DsRed reporter transgenes and hyperactive SB transposase gene SB100X with meIF promoter are
indicated. IR/DRs of SB are denoted by two short consecutive arrows. (B) Change of mean fluorescent intensity of DsRed between 2–4 weeks and 13–
15 weeks after transfection displayed as a box plot showing 10
th,2 5
th,5 0
th,7 5
th, and 90
th percentiles within each population with outliers shown
individually. * indicates p,0.05, Mann-Whitney U test. (C) Change in the % DsRed
+ cells in culture between 2–4 weeks and 13–15 weeks displayed as
box plot. * indicates p,0.05, Mann-Whitney U test. (D) Examples of progressive silencing of DsRed demonstrated by profiles from the 5 clones with
the greatest percent loss in DsRed expression for each vector. Shaded histogram, 2–4 weeks after transfection; solid histogram, 13–15 weeks after
transfection. (E) Examples of positive shift of DsRed expression demonstrated by five clones with the greatest gains in DsRed expression for each
vector term culture. Shaded histogram, 2–4 weeks after transfection; solid line, 13–15 weeks after transfection.
doi:10.1371/journal.pone.0029110.g007
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especially important in potential gene therapies where increasing
vector copy numbers to compensate for inactivation increases the
risk of harmful mutagenesis [14]. Insulators also play a role in
preventing local changes in gene expression due to insertion sites.
The appropriate regulation of an insulated IHK–b-globin
transgene is also important for potential therapies and in this
study we found no significant differences in transgene expression
upon differentiation between K562 cells transduced with insulated
or non-insulated vectors. Insulators combined with the erythroid-
specific IHK promoter could potentially confer long-term
therapeutic levels of hemoglobin for the treatment of sickle cell
disease, b-thalassemia, and other hemoglobinopathies utilizing
CD34
+ cells.
This combination of a highly efficient non-viral vector, a cargo
protected from epigenetic changes, and a tightly regulated
transgene is potentially of great utility in a clinical setting. Further
in vitro and in vivo studies are needed to evaluate the pKT2/meIF-
SB100X-IIbgI and variant vectors in primary hematopoietic cells
over long term experiments and the impact of such vectors on
disease models. Expanding on the results of this study will lead to
the development of a vector that will be suitable for clinical trials.
Methods
Sleeping Beauty transposon constructs
The cis pKT2-meIF-SB100X and trans pKT2-RV SB transpo-
son vectors were produced using standard molecular cloning
techniques (Figure 1). The hyperactive SB100X transposase gene
was driven by the constitutive murine eukaryotic initiation factor
4A1 promoter (Invitrogen, Carlsbad, CA) [22]. In order to protect
the transgenes from long-term silencing, we constructed SB
transposon vectors containing two insulator elements flanking
multiple restriction endonuclease recognition sites derived from
pIRES2-EGFP (Invitrogen) [31,42]. Chicken HS4 insulator
elements (1.2 kb) were transferred to the BamHI and SacI sites
of pIRES2-EGFP from the plasmid DNA construct, pJC13-1
(kindly provided by Dr. Gary Felsenfeld, NIDDK, NIH), by
digestion of pJC13-1 with XbaI or SacI, respectively [31]. Ends of
the released insulator elements and digested pIRES2-EGFP
vectors were modified to be compatible with the ligation. After
successful transfer of two cHS4 insulator elements into pIRES2-
EGFP, a DNA fragment encompassing two cHS4 insulator
elements and a partial multicloning site (MCS) between the
insulators was cloned into pKT2-meIF-SB100X or pKT2-RV SB
vectors by modification of DNA ends with Klenow, T4 DNA
polymerase and Antarctic Phosphatase (New England Biolabs,
Ipswitch, MA). This resulted in the insulated SB vectors, pKT2/
meIF-SB100X-Ins-MCS-Ins or pKT2/RV-Ins-MCS-Ins. The two
insulators encompassing the partial multicloning site were inserted
in the same, parallel direction to minimize loss of transgenes by
recombination. As a final step, the 3.2 kb IHK-b-globin transgene
fragment (Figure S10) was derived from pT2/IHK-b-globin//
eIF-SB10 by digestion with PstI, and introduced into the partial
MCS of pKT2/meIF-SB100X-Ins-MCS-Ins and pKT2/RV-Ins-
MCS-Ins. These constructs are hereafter referred to as pKT2/
meIF-SB100X-IIbgI and pKT2/RV-IIbgI, respectively. Control
SB-IHK-b-globin constructs with no insulator elements were made
by cloning the 3.2-kb IHK-b-globin transgene fragment into
pKT2-meIF-SB100X and pKT2-RV vectors by EcoRV digestion
and blunt-end ligations (pKT2/meIF-SB100X-Ibg and pKT2/
RV-Ibg, respectively).
SB vectors of cHS4-insulated CAGGS-DsRed fluorescent
transgene cassette were constructed with pKT2/meIF-SB100X-
Ins-MCS-Ins and pKT2/RV-Ins-MCS-Ins in a similar manner.
CAGGS-DsRed transgene was derived from digestion of
pCAGGS-DsRed with SpeI and HindIII, where DsRed
transgene was obtained with PCR from pDsRed-Express
(Clontech, Mountain View, CA) and cloned into pCAGGS
vector [43]. The CAGGS-DsRed transgene fragment was then
blunted by Klenow (New England Biolabs) and cloned into SalI
recognition site of pKT2/meIF-SB100X-Ins-MCS-Ins and
pKT2/RV-Ins-MCS-Ins, making pKT2/meIF-SB100X-Ins-
CAGGS-DsRed-Ins and pKT2/RV-Ins-CAGGS-DsRed-Ins,
respectively. Non-insulated control vectors, pKT2/meIF-
SB100X-CAGGS-DsRed and pKT2/RV-CAGGS-DsRed, were
generated by directly cloning SpeI-HindIII CAGGS-DsRed
transgene into original pKT2-meIF-SB100X and pKT2-RV,
via blunt-end ligation.
K562 cell culture, transfection, and isolation of single-cell
clones
K562 (ATCC catalog number CCL-243) cells were maintained
in RPMI 1640 (Invitrogen) supplemented with 10% FBS (Omega
Scientific, Tarzana, CA). Eighteen hours prior to transfection,
2610
6 cells were freshly plated in 100-mm Petri dishes in RPMI
1640 medium without antibiotics. Four mg of plasmid DNA
(pKT2/meIF-SB100X-Ins-CAGGS-DsRed-Ins or non-insulated
control vectors, pKT2/meIF-SB100X-CAGGS-DsRed) was trans-
fected using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. Cells were passaged to fresh medium
after 18 hours and DsRed
+ single-cell clones were sorted into 96-
well plates via FACSAria (BD Biosciences, San Jose, CA) or
manual isolation under epifluorescence microscopy. Single-cell
clones were then transferred to 24-well plates and maintained for
long-term ($12 weeks) studies.
K562 cells were also transfected with pKT2/meIF-SB100X-
IIbgI and pKT2/meIF-SB100X-Ibg as above and PCR screening
of clones for the IHK sequence and confirmation of b-globin
expression at 4 weeks after transfection was used to select clones
for long-term culture. b-globin expression was induced with
20 mM hemin added to the culture media for 72 hours prior to
collection for western blot analysis.
Figure 8. cHS4 insulator elements maintain long-term IHK–b-
globin expression. (A) Change in b-globin expression from 4 to 14
weeks after transfection displayed as a box plot showing 10
th,2 5
th,5 0
th,
75
th, and 90
th percentiles within each population with outliers for the
insulated pKT2/meIF-SB100X-IIbgI (n=18) and non-insulated pKT2/
meIF-SB100X-Ibg (n=20) clones. * indicates p,0.001, paired t-test. (B)
Fold increase in b-globin expression in response to hemin induction for
insulated (n=17) and non-insulated (n=23) clones. Data shown as
mean 6 SEM, difference between groups was not significant, p=0.62.
doi:10.1371/journal.pone.0029110.g008
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For analysis of K562 derived clones, western blot analysis was
conducted as previously described [26]. Nitrocellulose blots were
stained simultaneously with mouse antibodies against human b-
globin (sc-21757; Santa Cruz Biotechnology, Santa Cruz, CA) and
b-actin (AC-15; Sigma-Aldrich, St. Louis, MO) at 1:1000
dilutions. Blots were visualized using HRP-conjugated goat anti-
mouse secondary antibody (32430; Thermo Scientific, Rockford,
IL), Super Signal Dura substrate (34076, Thermo Scientific), and
X-ray film (BioMax; Eastman Kodak, Rochester, NY). For
analysis of CD34
+ derived cells, western blot analyses were
conducted as described previously [26,44]. Pre-cast SDS-PAGE
gels (Mini-PROTEAN TGX 4–20%; Bio-Rad, Hercules, CA)
were loaded with differentiated cell lysates, resolved at 100 volts,
and cut into upper and lower sections with the aid of a pre-stained
ladder at 25–30 kDa (GE Healthcare, Little Chalfont, United
Kingdom). The upper portion was transferred and analyzed for b-
actin as previously described [26]. The lower portion was
transferred and analyzed for b-globin using a modified technique
as reported [44]. The modified transfer for b-globin was
performed for 20 min at 30 volts and the membranes were fixed
in 16PBS with 0.4% paraformaldehyde for 30 min. Normal adult
human white blood cell lysate and red blood cell lysate were used
as controls.
Gel densitometry
Western blots of IHK–b-globin-transduced K562 clones were
analyzed using established guidelines [45]. Briefly, multiple
exposure lengths of each blot were scanned using an MP160
document scanner at highest resolution (Canon, Tokyo, Japan).
Images were quantified with FIJI v1.45 software (fiji.sc) using the
gel analysis tool set to integrate OD without calibration or
background correction. b-globin to b-actin ratios for all exposures
from each trial were calculated and the median of all
measurements was used as a measure of b-globin expression levels.
Nucleofection of CD34
+ cells
Cord blood mononuclear cells (MNCs) were separated using
Ficoll-Paque PLUS density medium (GE Healthcare). The
mononuclear fraction was subjected to ACK buffer (150 mM
NH4Cl, 10 mM KHPO4 and 0.1 mM EDTA, pH 7.4) lysis to
remove any residual red blood cells. Cells were washed three times
using 16 PBS containing 0.5% BSA and 2 mM EDTA (all
Invitrogen); and CD34
+ cells were separated using Miltenyi
MACS CD34 magnetic beads (Miltenyi Biotechnology, Bergisch
Gladbach, Germany) according to the manufacturer’s instructions.
CD34
+ purity was assessed using flow cytometry and was .90% in
all cases (Figure S11). Cells were counted and resuspended at
0.75 to 1610
6 cells per 100 ml of CD34
+ complete Nucleofection
solution (Lonza, Basel, Switzerland). Cells were mixed with
plasmid DNA and nucleofected using the Amaxa Nucleofector
II with program U-008. Nucleofected cells were immediately
removed into pre-warmed and equilibrated recovery medium
consisting of X-VIVO 10 without phenol red or gentimycin
(Lonza), 100 ng/ml Stem Cell Factor (SCF), 10 ng/ml IL-3,
10 ng/ml Flt-3L (all Invitrogen) and cultured in 6-well plates for
2 hours prior to differentiation.
Differentiation of CD34
+ cells
Erythroid differentiation was carried out on MS-5 stromal cells as
previously described [46,47]. Briefly, 2610
4 cells were plated in 2 mL
serum-free expansion medium containing 100 ng/ml SCF, 5 ng/ml
IL-3, 3 U/ml erythropoietin (EPO), and 1 mM hydrocortisone
(Sigma-Aldrich) and cultured in 6-wells plates at 37uCa n d5 %C O 2
for 4 days. The cells were then diluted into 6 ml of the same medium in
a2 5c m
2 flask and cultured for an additional 4 days. Expanded cells
were washed with basal medium and resuspended in 25 ml of basal
medium with 3 U/ml EPO and plated onto a newly confluent 75 cm
2
flask of MS-5 feeder cells and cultured for 3 days. For final maturation,
erythroid cells were co-cultured on feeder cells for 10 days using basal
medium without cytokines with one medium change after 5 days at
which time 2610
6 cells were harvested for nucleic acid purification. T-
cell differentiation was carried on OP9 stromal cells as previously
described [48]. Briefly, 5610
4 nucleofected cells were resuspended in
aMEM (Invitrogen) with 20% FBS (Atlanta Biologicals, Lawrenceville,
GA), 5 ng/ml IL-7, and 5 ng/ml Flt3L (both Peprotech, Rocky Hill,
NJ) onto sub-confluent OP9-DLL1 cells. Fresh media with cytokines
was replaced every 3 to 4 days. B-cell differentiation was carried out on
MS-5 stromal cells as reported [36]. Briefly, 1.5610
5 nucleofected
CD34
+ cells were resuspended in 15 ml of aMEM with 10% FBS,
10 ng/ml SCF, and 10 ng/ml G-CSF and seeded onto a confluent
MS-5 layer in a 75 cm
2 flask. Ten milliliters of fresh medium was
added after 7 days and cells were maintained with twice weekly half-
media changes. Myeloid and granulocyte differentiations were
performed on MS-5 stromal cells as described [23,49]. Briefly, 10
5
nucleofected CD34
+ cells were seeded in 1 ml IMDM with 10% FBS,
2 mM L-alanyl-glutamine, 50 ng/ml SCF, and 50 ng/ml IL-3 in six-
well plates. After 3 days in culture, cells were washed and seeded into
25 cm
2 flasks in basal medium plus 50 ng/ml SCF, 50 ng/ml IL-3,
and 10 ng/ml G-CSF. Cells were maintained at 2610
5 to 8610
5 cells
per ml in complete medium with cytokines for 10 days until harvest.
Colony forming assays
Colony forming assays were performed using MethoCult 4435
as recommended by the manufacturer (StemCell Technologies,
Vancouver, Canada). Cells were seeded in quadruplicate and
colonies were scored after 14–16 days using an Olympus IX70
epifluorescence light microscope (Olympus, Tokyo, Japan).
Digital images were batch processed using ImageMagick 6.0
(imagemagick.org).
Flow cytometry
Cell surface markers were characterized using fluorochrome-
conjugated antibodies specific for human antigens: CD34-Alexa-
Fluor647 (4H11; eBioscience, San Diego, CA), CD1a-FITC (HI149;
BD Pharmingen), CD3-V450 (HIT3a; BD Horizon), CD7-Alexa-
Fluor700 (M-T701; BD Pharmingen), CD14-V450 (MphiP9; BD
Horizon), CD15-PE-Cy7 (HI98; BD Pharmingen), CD19-Alexa-
Fluor700, CD33-AlexaFluor700, CD45-V500 (HI30; BD Horizon),
CD45-PerCP-Cy5.5 (1D2; eBioscience), CD71-PE (OKT9;
eBioscience), and CD235a-FITC (HIR2; eBioscience). Cells were
labeled in staining buffer (16Hanks Balanced Salt Solution without
Ca
2+or Mg
2++2% FBS+1 mM EDTA) inantibody dilutions of 1:100
at a concentration of 10
7 cells per ml. Viability was assessed using 7-
AAD (Southern Biotech, Birmingham, AL) or eFluor780 Fixable
Viability Dye (eBioscience) and dead cells excluded from analysis.
DNA content was assessed using DRAQ5 according to the
manufacturer’s instructions (eBioscience). Data acquisition was
performed using a BD LSRII flow cytometer (BD Biosciences). Cell
sorting was performed using a BD FACS Aria (BD Biosciences). Flow
cytometric data was analyzed using FlowJo 7.6.4 software (Tree Star
Inc).
Sample collection
Cells were harvested and frozen in liquid nitrogen until processed.
DNA, RNA, and protein were purified using the Qiagen AllPrep Mini
kit (Qiagen, Valencia, CA). Briefly, progressive collection from sample
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RNA collection with RNeasy columns, and protein precipitation and
washing using Buffer APP as recommended by the manufacturer. For
HPLC analysis of hemoglobin, 1.5610
7 non-adherent erythroid cells
were pelleted and lysed using 50 ml of HPLC grade water (Invitrogen);
crude lysate was centrifuged at 18,0006 g, and cleared lysate was
frozen in liquid nitrogen and stored at 280uC prior to analysis.
PCR analysis
SB and IHK DNA detection was done in a multiplex format using
Qiagen HotStarTaq hot-start PCR system using primers IG2, BAG3,
and SS9, for HS40/Ankyrin-1 junction in the IHK promoter, an
Intron/Exon junction in b-Actin, and the SB100X coding sequence,
respectively (Table S1). Sixty ng of genomic DNA was used from each
test condition and the reaction was assembled according to the
manufacturer’s instructions and amplified using a two-phase cycle to
promote amplification of low-levels of SB100X DNA (Figure S4,
Table S1). RT-PCR for b-globin and b-actin was conducted as
previously described [26]. Briefly, 20 ng of total RNA was amplified
with primers specific for b-actin and b-globin using the Titan One
Tube RT-PCR kit (Roche Applied Sciences, Indianapolis, IN)
according to the manufacturer’s instructions (Primers BAM1 and
BGM1; Table S1).R T - P C Rf o rSB100X was performed using
primer set SS9 which is specific for the SB coding sequence and 100 ng
of total RNA.
HPLC analysis
Globin chains were identified using a modification of the
method described earlier [50]. An Agilent 1200 HPLC system
(Santa Clara, CA) was used with a C4 column, a water/
acetonitrile/trifluoroacetic acid gradient run at 0.7 ml/min at
23uC, and spectroscopic detection at 220 nm.
Statistical analysis
Statistical significance of data was performed using SigmaStat
3.5 software (Systat Software, Chicago, IL).
Supporting Information
Figure S1 DsRed
2 CFUs imaged with a bright field
filter (top row), pan-fluorescence filter (middle row),
and rhodamine fluorescence filter (bottom row).
(TIF)
Figure S2 Homogeneous DsRed
+ CFUs imaged with a
bright field filter (top row), pan-fluorescence filter
(middle row), and rhodamine fluorescence filter (bot-
tom row).
(TIF)
Figure S3 Heterogeneous DsRed
+ CFUs imaged with a
bright field filter (top row), pan-fluorescence filter
(middle row), and rhodamine fluorescence filter (bot-
tom row).
(TIF)
Figure S4 Sensitivity test of SB100X multiplex detec-
tion. Sixty mg of normal human genomic DNA was spiked with
5000 copies of pKT2/IHK-b-globin plasmid and varying amounts
of pUbC-SB100X plasmid and amplified as described in text.
(TIF)
Figure S5 Western blot sensitivity test for b-globin. Fifty
mg of white blood cell lysate was spiked with varying amounts of
adult hemoglobin from red blood cell hypotonic lysate, which was
quantified directly using Drabkin’s method at 540 nm. (A) Samples
analyzed using modification of previously reported protocol [44].
(B) Samples analyzed using standard methodology [27].
(TIF)
Figure S6 Western blot of IHK-b-globin trial 2.
(TIF)
Figure S7 Western blot of IHK-b-globin trial 3.
(TIF)
Figure S8 RT-PCR of IHK-b-globin trial 2.
(TIF)
Figure S9 RT-PCR of IHK-b-globin trial 3.
(TIF)
Figure S10 Schematic of the IHK–b-globin transposon
components.
(TIF)
Figure S11 Assessment of CD34
+ purity prior to nucleo-
fection in IHK–b-globin trials.
(TIF)
Table S1 Primers and PCR cycles.
(XLS)
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